Stifel initiated coverage of Oruka Therapeutics with a Buy rating and $49 price target The firm views the rapid uptake of Bimzelx in psoriasis since U.S. approval in 2023 as “clear empirical evidence that raising an already high bar drives meaningful demand” and in that context says that Oruka’s approach to even greater innovation includes building upon the “two best targets to date in psoriasis,” ORKA-001 and ORKA-002. There remains potential for additional upside to the firm’s model for ORKA-002 outside psoriasis, the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics initiated with a Buy at H.C. Wainwright
- Oruka Therapeutics Adjusts Executive Severance Agreements
- Oruka Therapeutics announces preclinical data for ORKA-001
- Oruka Therapeutics initiated with an Outperform at Leerink
- Oruka Therapeutics initiated with an Outperform at LifeSci Capital
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue